Roivant Sciences Ltd (87S)
XMUN 
Summary
87S Chart
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis Transcript
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis Transcript
Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately
Roivant Sciences NASDAQ: ROIV said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered commercial launch.
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon
Roivant Sciences is transitioning from an asset-monetization platform to a commercial-stage biopharma, supported by a strong cash position and imminent product launches. ROIV's $4.7 billion pro forma liquidity eliminates near-term dilution risk, enabling commercialization of brepocitinib and continued pipeline investment without adverse equity market reliance. Brepocitinib's FDA Priority Review for dermatomyositis, with potential approval by September 2026, anchors near-term upside, while label expansions target a >280,000 patient opportunity.
Roivant Sciences Ltd (87S) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Roivant Sciences Ltd ever had a stock split?
Roivant Sciences Ltd Profile
| Biotechnology Industry | Healthcare Sector | Matthew Gline CEO | XMUN Exchange | BMG762791017 ISIN |
| GB Country | 721 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company with a focus on the development and commercialization of innovative medicines primarily within the inflammation and immunology sectors. With its unique model, known as Vants, Roivant aims to efficiently develop and bring to market its therapeutic technologies and medicines. This model collaborates with biopharmaceutical businesses, discovery-stage companies, and health technology startups. Founded in 2014 and headquartered in London, the United Kingdom, Roivant Sciences has established strategic collaborations and licensing agreements with industry leaders such as Boehringer Ingelheim International, GmbH, and Japan Tobacco Inc., to enhance its discovery and development efforts across a range of therapeutic areas.
Products and Services
- VTAMA: A novel topical medication approved for the treatment of psoriasis, and currently under development for the treatment of atopic dermatitis. VTAMA represents Roivant’s foray into dermatological treatments, highlighting their commitment to addressing skin conditions with innovative solutions.
- IMVT-1402 and batoclimab: These are fully human monoclonal antibodies targeting the neonatal Fc receptor, with development spanning various IgG-mediated autoimmune diseases. These innovative treatments exemplify Roivant’s approach to tackling autoimmunity through targeted antibody therapies.
- brepocitinib: A dual inhibitor of TYK2 and JAK1, brepocitinib is in development for multiple inflammatory conditions, including dermatomyositis and non-infectious uveitis. This potent small molecule underscores Roivant’s commitment to developing therapies that modulate the immune system to treat diseases.
- Namilumab: As a fully human anti-GM-CSF monoclonal antibody, Namilumab is currently under a Phase 2 clinical trial, targeting a range of inflammatory and autoimmune disorders. This treatment option further represents Roivant’s focus on novel immune-modulating therapeutic agents.
- Delivery Platforms: Roivant is working on enhancing drug delivery mechanisms, including a lipid nanoparticle platform and a ligand conjugate platform. These platforms are part of Roivant’s broader strategy to improve the efficacy and delivery of treatments.
- Collaborations: The company has forged significant partnerships, notably with Boehringer Ingelheim International, GmbH for the development of RNA-targeting compounds, and with Japan Tobacco Inc., securing the rights to develop, register, and market tapinarof in Japan for psoriasis and atopic dermatitis. These collaborations are vital to Roivant’s strategy of leveraging external expertise and markets to broaden its therapeutic impact.
